John Allinson,
Head of Biomarker Strategy,
LGC Limited
• 40+ years of experience developing and working with novel and diagnostic biomarkers
• Covering all therapeutic categories and phases of development.
• Co-Author to the first consensus white paper on biomarker assay validation requirements in Drug Development as a Member of the AAPS Ligand Binding Assay Bioanalytical Focus Group (LBABFG) Biomarker Committee
• Authored Book chapter on use of commercial biomarker assays in drug development
• Currently working on several committees with a view to bringing forward further white papers in the area of Biomarker analysis including Multiplex assays.
John Allinson, Leads the Biomarker Strategy of LGC and brings over 40 years of experience in developing and working with biomarkers including their use in drug development across all therapeutic categories and phases of development. Before joining LGC, Mr. Allinson spent 22 years in NHS Clinical Pathology services before moving into the CRO industry where he managed the Central Laboratory for Covance in Harrogate before leading the biomarker laboratories at BAS International and more recently Veeda and ICON Laboratories which acquired Veeda Laboratories in 2009. Mr. Allinson was part of the AAPS Ligand Binding Assay Bioanalytical Focus Group (LBABFG) Biomarker Committee which published the first consensus white paper on biomarker assay validation requirements.
|
|
|
Add to Calendar ▼2014-07-08 10:30:002014-07-08 11:30:00Europe/LondonCase Studies of Analytical Platform/Assay Specific Challenges for Biomarker Assays Used in Drug Development and a Look at the Differences in Validation Exercises/Requirements for Research and Diagnostic AssaysBiomarkers 2014 in Cambridge, UKCambridge, UKSELECTBIOenquiries@selectbiosciences.com
